Treating Heart Failure With hPSC-CMs

Inclusion criteria 1. Aged 35-75 (including 35 and 75). 2. Have signed the Informed Consent Form (ICF). 3. Patients have chronic left ventricular dysfunction. 4. Patients have NYHA Class III-IV cardiac function even after improved medication for the treatment of advanced chronic heart failure. 5. Patients have indications for Coronary Artery Bypass Grafting. 6. 20% ≤ LVEF ≤ 45% as determined by echocardiogram (data collected up to 6 months prior to inclusion evaluation are valid; data collected within 1 month since a myocardial infarction are invalid). 7. Weakening or absence of segmental regional wall motion as determined by standard imaging. Exclusion criteria 1. PRA ≥ 20% or DSA-positive. 2. Patient received ICD transplantation, CRT or similar treatment. 3. Patients with valvular heart disease or received heart valvular disease 4. Patients received treatment of percutaneous transluminal coronary intervention (PCI) 5. Patients with atrial fibrillation 6. Patients previously suffered sustained ventricular tachycardia or sudden cardiac death. 7. Baseline glomerular filtration rate \<30ml/min/1.73m2. 8. Liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN. 9. Hematological abnormality: A hematocrit \<25% as determined by HCT, white blood cell\<2500/ul or platelet values \<100000/ul without another explanation. 10. Known, serious radiographic contrast allergy, penicillin allergy, streptomycin allergy. 11. Coagulopathy (INR\>1.3) not due to a reversible cause. 12. Contra-indication to performance of a MRI scan. 13. Recipients of organ transplant. 14. Clinical history of malignancy within 5 years (patients with prior malignancy must be disease free for 5 years). 15. Non-cardiac condition that limits lifespan \<1 year. 16. On chronic therapy with immunosuppressant medication, such as glucocorticoid and TNFα antagonist. 17. Patients allergy to or cannot use immunosuppressant. 18. Serum positive for HIV, HBV, HCV, TP. 19. Currently enrolled other investigational therapeutic or device study. 20. Patients who are pregnant or breast feeding. 21. Other conditions that researchers consider not suitable to participate in this study.